Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial

BACKGROUND: Sarilumab is a human monoclonal antibody directed against the alpha subunit of the interleukin-6 receptor complex. In the MOBILITY phase III randomized controlled trial (RCT), sarilumab + methotrexate (MTX) treatment resulted in clinical improvements at 24 weeks that were maintained at 5...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Arthritis Res Ther
Glavni autori: Strand, Vibeke, Kosinski, Mark, Chen, Chieh-I, Joseph, George, Rendas-Baum, Regina, Graham, Neil M. H., van Hoogstraten, Hubert, Bayliss, Martha, Fan, Chunpeng, Huizinga, Tom, Genovese, Mark C.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5012017/
https://ncbi.nlm.nih.gov/pubmed/27600829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-1096-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items